Previous studies [24, 25] showed that FGFR inhibitors were effective to block tumor proliferation in a subset of NSCLC cell lines with FGFR1 amplification and led to significant tumor shrinkage. Here, FGFR1 is linked to non-small cell lung carcinoma.